Shattuck Labs (NASDAQ:STTK) Stock Price Down 1.3% – Here’s Why

Shattuck Labs, Inc. (NASDAQ:STTK) shares fell 1.3% on Monday . The company traded as low as $2.82 and last traded at $3.06. 389,755 shares traded hands during trading, an increase of 21% from the average session volume of 322,840 shares. The stock had previously closed at $3.10.

Wall Street Analyst Weigh In

STTK has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Shattuck Labs in a report on Wednesday, October 8th. Wall Street Zen raised Shattuck Labs from a “sell” rating to a “hold” rating in a research note on Saturday, September 13th. HC Wainwright raised Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a research note on Monday, December 1st. Finally, Wedbush assumed coverage on shares of Shattuck Labs in a research report on Monday, September 8th. They set an “outperform” rating and a $4.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Shattuck Labs presently has an average rating of “Moderate Buy” and an average target price of $4.00.

Shattuck Labs Stock Down 1.3%

The company has a market cap of $193.64 million, a price-to-earnings ratio of -3.00 and a beta of 1.70. The stock’s 50-day simple moving average is $2.19 and its 200 day simple moving average is $1.56.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. The company had revenue of $1.00 million during the quarter. On average, sell-side analysts expect that Shattuck Labs, Inc. will post -1.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Shattuck Labs

A number of institutional investors have recently modified their holdings of STTK. Bank of America Corp DE lifted its stake in Shattuck Labs by 2,968.2% during the 3rd quarter. Bank of America Corp DE now owns 1,131,888 shares of the company’s stock worth $2,705,000 after acquiring an additional 1,094,997 shares in the last quarter. Virtu Financial LLC purchased a new stake in Shattuck Labs during the third quarter worth about $38,000. Orbimed Advisors LLC acquired a new stake in shares of Shattuck Labs during the third quarter worth about $15,072,000. Two Sigma Investments LP boosted its stake in shares of Shattuck Labs by 431.1% in the third quarter. Two Sigma Investments LP now owns 408,598 shares of the company’s stock valued at $977,000 after purchasing an additional 331,664 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in Shattuck Labs during the 3rd quarter worth approximately $46,000. 58.74% of the stock is owned by institutional investors and hedge funds.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.